Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 6/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099769 | 0.91 | PIK3CA (0.33) | NTRK1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL8043913 | 0.89 | PIK3CA (0.36) | PIK3CA | |
| SCHEMBL8049886 | 0.87 | NTRK1 (0.34) | NTRK1NTRK3NTRK2PIK3CAPIK3CD | |
| SCHEMBL13099776 | 0.83 | EGFR (0.34) | NTRK1NTRK3NTRK2 | |
| SCHEMBL13099770 | 0.82 | SIGMAR1 (0.35) | NTRK1PIK3CAPIK3CD | |
| SCHEMBL8032410 | 0.82 | DYRK1A (0.43) | PIK3CB | |
| SCHEMBL13099773 | 0.81 | GRM4 (0.38) | NTRK1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL8054838 | 0.80 | PIK3CA (0.36) | PIK3CA | |
| SCHEMBL8041870 | 0.77 | PIK3CA (0.34) | PIK3CA | |
| SCHEMBL13099768 | 0.75 | PRMT5 (0.37) | PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| WO-2009038385-A2 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MAP3K20, MAP3K3, MAP3K1 | NTRK1 2358/4885NTRK3 1930/4885NTRK2 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.